Figure 1.

The elevation of FAM3D correlates with the pathogenesis of hypertension

(A) ELISA measurement of plasma FAM3D from individuals in the case-control study. N = 80 pairs. Data are represented as mean ± SEM. Mann-Whitney test.

(B) Spearman correlation analysis of plasma FAM3D levels and SBP in patients with hypertension. N = 80.

(C) ELISA measurement of plasma FAM3D levels in C57BL/6 mice treated with saline or AngII for 7 days. n = 5–6. Data are represented as mean ± SEM. Unpaired Student’s t test, ∗p < 0.05.

(D and E) Immunofluorescent staining of FAM3D in mesenteric arteries (E) and thoracic aortas (F) from C57BL/6 mice after saline or AngII infusion for 7 days. Scale bar, 40 μm.

(F) Immunofluorescent en face staining of FAM3D in the endothelial layer of thoracic aortas of C57BL/6 mice after saline or AngII infusion for 1 day or 7 days. Scale bar, 25 μm. n = 6. Data are represented as mean ± SEM. Unpaired Student’s t test, ∗p < 0.05.

(G) Immunofluorescent en face staining of FAM3D in the endothelial layer of thoracic aortas of sham-treated or DOCA-salt-induced mice. Scale bar, 25 μm. n = 6. Data are represented as mean ± SEM. Unpaired Student’s t test, ∗p < 0.05.

(H) Immunofluorescent en face staining of FAM3D in the endothelial layer of thoracic aortas of Wistar-Kyoto (WKY) or SHRs. Scale bar, 25 μm. n = 6. Data are represented as mean ± SEM. Unpaired Student’s t test, ∗p < 0.05.